Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis

Leyh, Catherine; Ehmer, Ursula; Rössler, Daniel; Philipp, Alexander B.; Reiter, Florian P.; Jeliazkova, Petia; Jochheim, Leonie S.; Jeschke, Matthias; Hammig, Janina; Ludwig, Johannes M.; Theysohn, Jens M.; Geier, Andreas und Lange, Christian M. (2022): Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis. In: Cancers, Bd. 14, Nr. 8

Abstract

Simple Summary An increasing number of new systemic therapies have significantly enhanced treatment opportunities for patients with advanced liver cancer. Yet, it is unclear which sequence of systemic therapies is best for individual patients. In the present study, we compared systemic treatment lines in patients who received either first-line therapy with sorafenib or lenvatinib, two important tyrosine-kinase inhibitors for the treatment of liver cancer. Overall, baseline liver function rather than choice of first-line tyrosine kinase inhibitor (TKI) had an impact on median overall survival (mOS). The optimal treatment sequence of tyrosine kinase inhibitor (TKI)-based therapy in patients with hepatocellular carcinoma (HCC) remains unclear. Therefore, sequential systemic therapy after first-line therapy with sorafenib or lenvatinib was compared in a retrospective real-world cohort. In total, 164 patients with HCC were included. Child B cirrhosis was present in 26 patients (16.5%), whereas 132 patients (83.5%) had preserved liver function. In total, 72 patients (44%) discontinued systemic therapy after first-line therapy while 51 (31%) and 31 (19%) patients received 2 or more treatment lines. Most notably, median overall survival (mOS) was influenced by liver functional status and patient performance status at the beginning of first-line therapy. Patients receiving a sequential therapy regimen had significantly longer mOS compared to patients that discontinued systemic therapy after omitting first-line treatment. The choice of the initial TKI did not impact mOS. A clear deterioration of liver function could be observed during the course of TKI-based treatment.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• Sprache: Englisch
• DFG: Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 491502892